Core Viewpoint - XuanZhu Biotech-B (02575) has successfully listed, with an initial share price of HKD 11.60, raising approximately HKD 701 million from the issuance of 67.33 million shares, and has seen a significant price increase of 153.97% to HKD 29.46 at the time of reporting [1] Company Overview - XuanZhu Biotech is an innovation-driven Chinese biopharmaceutical company that has established a comprehensive internal R&D platform since the acquisition by Sihuan Pharmaceutical Holdings Group in 2008 [1] - The company has over ten drug assets actively in development, targeting diseases such as gastrointestinal disorders, tumors, and non-alcoholic fatty liver disease (NASH) [1] Product Pipeline - The company has three core products: - KBP-3571, an innovative proton pump inhibitor (PPI) for gastrointestinal diseases, which has received NDA approval - XZP-3287, a CDK4/6 inhibitor targeting breast cancer, also NDA approved - XZP-3621, an ALK inhibitor for non-small cell lung cancer (NSCLC), which has received NDA approval [2] - The product pipeline is strategically designed to balance development risks and innovation, allowing commercialized or late-stage assets to support the development of early-stage innovative drugs [2]
新股首日 | 轩竹生物-B(02575)首挂上市 早盘高开153.97% 旗下已有三款产品获批上市